Terms ending in 2032
Yeda Research and Development Co. Ltd.
Every in-force patent on Yeda Research and Development Co. Ltd.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,365,828 | Genetically Modified Muscle Cells Which Express Neurotrophic Factors In force · High confidence | Yeda Research and Development Co. Ltd. | In force | High confidence | |
| US 10,744,162 | Genetically Modified Muscle Cells Which Express Neurotrophic Factors In force · Medium confidence | Ramot at Tel-Aviv University Ltd. | In force | Medium confidence | |
| US 9,067,052 | Magnetic Configuration and Timing Scheme for Transcranial Magnetic Stimulation In force · High confidence | Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science | In force | High confidence | |
| US 11,491,301 | Device and Method for Controlling Respiration During Sleep In force · Medium confidence | Yeda Research and Development Co. Ltd. | In force | Medium confidence | |
| US 10,288,622 | Use of Akt Phosphorylation as a Biomarker for Prognosing Neurodegenerative Diseases and Treating Same In force · Medium confidence | Yeda Research and Development Co. Ltd. | In force | Medium confidence | |
| US 9,623,049 | Immunotherapy Using Redirected Allogeneic Cells In force · High confidence | Yeda Research and Development Co. Ltd. | In force | High confidence | |
| US 9,150,858 | Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions In force · High confidence | Yeda Research and Development Co. Ltd. | In force | High confidence | |
| US 9,901,593 | Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions In force · Medium confidence | Yeda Research and Development Co. Ltd. | In force | Medium confidence | |
| US 10,238,681 | Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions In force · Medium confidence | Yeda Research and Development Co. Ltd. | In force | Medium confidence | |
| US 12,016,876 | Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions In force · Medium confidence | Yeda Research and Development Co. Ltd. | In force | Medium confidence | |
| 9 more term ends in 2032 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
17 of these are in force and held by Yeda Research and Development Co. Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.